Pharmacy Retail
Key highlights
- India’s pharmacy retail market remains highly fragmented, with organised chains and e-pharmacies gaining share through store expansion, digital fulfilment and broader wellness assortments.
- MedPlus delivered Q2 FY2027 consolidated revenue growth of 21.3% YoY to ₹2,037.11 Cr, led by a 166-store net addition and 13.2% YoY growth from mature stores.
- Profit conversion remained weak: Q2 FY2027 PAT increased only 1.0% YoY to ₹56.07 Cr as gross margin declined 110 bps YoY and lease-related depreciation and finance costs increased.
- Mature-store economics remain attractive, with stores older than 12 months reporting 11.7% store-level EBITDA margin and 72.0% annualised operating ROCE in Q2 FY2027.
- Private labels remain the principal structural margin lever, but MedPlus’s private-label revenue declined 0.6% YoY in Q2 FY2027 amid customer resistance to prescription-drug substitution.
- Quick commerce, e-pharmacies, government generic-drug outlets and tighter prescription-drug advertising rules increase competitive and compliance intensity across Indian Pharmacy Retail.
powered by IRIS
Unlock full access to this sectoral analysis with in-depth insights, comprehensive data, and exclusive reports.


